NASDAQ Healthcare Biotechnology MDWD

MediWound Ltd.

$ 14.24 0.28 %

MediWound Ltd., an Israeli biopharmaceutical company established in 2000 and based in Yavne, focuses on the innovation, production, and sale of advanced biological treatments for the healing and regrowth of damaged tissues. The company's key commercialized product is NexoBrid, a biological drug distributed to specialized burn centers and hospital burn units. NexoBrid is specifically formulated for the enzymatic debridement of eschar—dead or compromised tissue—in adults suffering from severe thermal burns, encompassing deep partial-thickness and full-thickness injuries. Furthermore, MediWound's development pipeline includes EscharEx, which has successfully concluded Phase II clinical trials for addressing chronic and other intractable wounds. Another investigational therapy, MW005, is currently undergoing Phase I/II clinical studies for the treatment of low-risk basal cell carcinoma.

CEO: Ofer Gonen - https://www.mediwound.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

$27 89.61 %

Recommandation

Buy

DCF

$ -26.27

Loading data...

MDWD vs S&P500

Loading data...

No data available.

Quick ratio

2.19

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

-6.30

may indicate that the company is undervalued or has poor growth prospects.

EPS

-2.26

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-67.22 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-47.30 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

5.30

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.20

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

-1.89

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
3 indicates worrying financial health
Altman score
2.36 indicates an uncertain financial situation
Loading data...

No data available.

Cash / Debt

Cash Ratio
2.06 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.10 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.